Increasing procoagulant activity of circulating microparticles
in patients with Philadelphia-negative myeloproliferative
neoplasms: a single-centre experience

J 2015

Increasing procoagulant activity of circulating microparticles in patients with Philadelphia-negative myeloproliferative neoplasms: a single-centre experience

KISSOVÁ, Jarmila; Petra OVESNÁ; Alena BULIKOVÁ; Jiřina ZAVŘELOVÁ; Miroslav PENKA et al.

Základní údaje

Originální název

Increasing procoagulant activity of circulating microparticles in patients with Philadelphia-negative myeloproliferative neoplasms: a single-centre experience

Autoři

KISSOVÁ, Jarmila; Petra OVESNÁ ; Alena BULIKOVÁ; Jiřina ZAVŘELOVÁ a Miroslav PENKA

Vydání

BLOOD COAGULATION & FIBRINOLYSIS, Philadelphia, Lippincott Williams & Wilkins, 2015, 0957-5235

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.242

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/15:00083018

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

microparticle; myeloproliferative neoplasms; procoagulant activity; thrombosis

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 6. 2015 09:36, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Microparticles are small membrane fragments with dimension between 0.1 and 1 mu m, which are released during cell activation or apoptosis, exposing the phospholipid phosphatidylserine and membrane antigens typical for cellular origin. Philadelphia-negative myeloproliferative neoplasms (MPNs) are characterized by an increased risk of thrombosis. Data from literature suggest an association between thrombosis and the procoagulant activity of microparticles. Association between the procoagulant activity of microparticles and the incidence of thrombosis was assesed in a group of 126 patients with Philadelphia-negative MPNs. Measurement of microparticles procoagulant activity was performed using a functional assay, namely the Zymuphen MP-activity (Hyphen Biomed, Neuville-sur-oise, France). A total of 539 samples were analysed within this group of patients, regardless of patients' state of health. A significantly higher circulating microparticles procoagulant activity was found in MPN patients as compared with the control group (P<0.001). A pathological level of procoagulant activity was observed more frequently in patients with polycythaemia vera (88%, P=0.002) than groups of patients with essential thrombocythaemia (73.2%) and primary myelofibrosis (68.3%); the same result was confirmed in patients with a history of venous thrombosis in comparison with patients without thrombosis (84.7 vs. 73.2%, P=0.029). Patients without cytoreductive treatment had a higher activity of microparticles (P=0.010). Furthermore, presence of JAK2 V617F mutation was associated with an increased procoagulant activity (P=0.007), as well as the higher JAK2 V617F allele burden (P=0.001). Further prospective clinical studies will be necessary to evaluate the clinical relevance of microparticles in the prediction hypercoagulable state in these patients.

Návaznosti

MUNI/A/0723/2012, interní kód MU

Název: Nové klinické a diagnostické přístupy u hematogických malignit (Akronym: NoKliDiPřiHeMa)

Investor: Masarykova univerzita, Nové klinické a diagnostické přístupy u hematogických malignit, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

Citovat

KISSOVÁ, Jarmila; Petra OVESNÁ; Alena BULIKOVÁ; Jiřina ZAVŘELOVÁ a Miroslav PENKA. Increasing procoagulant activity of circulating microparticles in patients with Philadelphia-negative myeloproliferative neoplasms: a single-centre experience. BLOOD COAGULATION & FIBRINOLYSIS. Philadelphia: Lippincott Williams & Wilkins, 2015, roč. 26, č. 4, s. 448-453. ISSN 0957-5235. Dostupné z: https://doi.org/10.1097/MBC.0000000000000293.

@article{1300333,
   author = {Kissová, Jarmila and Ovesná, Petra and Buliková, Alena and Zavřelová, Jiřina and Penka, Miroslav},
   article_location = {Philadelphia},
   article_number = {4},
   doi = {https://doi.org/10.1097/MBC.0000000000000293},
   keywords = {microparticle; myeloproliferative neoplasms; procoagulant activity; thrombosis},
   language = {eng},
   issn = {0957-5235},
   journal = {BLOOD COAGULATION & FIBRINOLYSIS},
   title = {Increasing procoagulant activity of circulating microparticles in patients with Philadelphia-negative myeloproliferative neoplasms: a single-centre experience},
   volume = {26},
   year = {2015}
}

TY  - JOUR
ID  - 1300333
AU  - Kissová, Jarmila - Ovesná, Petra - Buliková, Alena - Zavřelová, Jiřina - Penka, Miroslav
PY  - 2015
TI  - Increasing procoagulant activity of circulating microparticles in patients with Philadelphia-negative myeloproliferative neoplasms: a single-centre experience
JF  - BLOOD COAGULATION & FIBRINOLYSIS
VL  - 26
IS  - 4
SP  - 448-453
EP  - 448-453
PB  - Lippincott Williams & Wilkins
SN  - 09575235
KW  - microparticle
KW  - myeloproliferative neoplasms
KW  - procoagulant activity
KW  - thrombosis
N2  - Microparticles are small membrane fragments with dimension between 0.1 and 1 mu m, which are released during cell activation or apoptosis, exposing the phospholipid phosphatidylserine and membrane antigens typical for cellular origin. Philadelphia-negative myeloproliferative neoplasms (MPNs) are characterized by an increased risk of thrombosis. Data from literature suggest an association between thrombosis and the procoagulant activity of microparticles. Association between the procoagulant activity of microparticles and the incidence of thrombosis was assesed in a group of 126 patients with Philadelphia-negative MPNs. Measurement of microparticles procoagulant activity was performed using a functional assay, namely the Zymuphen MP-activity (Hyphen Biomed, Neuville-sur-oise, France). A total of 539 samples were analysed within this group of patients, regardless of patients' state of health. A significantly higher circulating microparticles procoagulant activity was found in MPN patients as compared with the control group (P<0.001). A pathological level of procoagulant activity was observed more frequently in patients with polycythaemia vera (88%, P=0.002) than groups of patients with essential thrombocythaemia (73.2%) and primary myelofibrosis (68.3%); the same result was confirmed in patients with a history of venous thrombosis in comparison with patients without thrombosis (84.7 vs. 73.2%, P=0.029). Patients without cytoreductive treatment had a higher activity of microparticles (P=0.010). Furthermore, presence of JAK2 V617F mutation was associated with an increased procoagulant activity (P=0.007), as well as the higher JAK2 V617F allele burden (P=0.001). Further prospective clinical studies will be necessary to evaluate the clinical relevance of microparticles in the prediction hypercoagulable state in these patients.
ER  -

KISSOVÁ, Jarmila; Petra OVESNÁ; Alena BULIKOVÁ; Jiřina ZAVŘELOVÁ a Miroslav PENKA. Increasing procoagulant activity of circulating microparticles in patients with Philadelphia-negative myeloproliferative neoplasms: a single-centre experience. \textit{BLOOD COAGULATION \&{} FIBRINOLYSIS}. Philadelphia: Lippincott Williams \&{} Wilkins, 2015, roč.~26, č.~4, s.~448-453. ISSN~0957-5235. Dostupné z: https://doi.org/10.1097/MBC.0000000000000293.

Přehled o publikaci